

ZIOPHARM ONCOLOGY INC  
Form 8-K  
May 22, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of report (Date of earliest event reported): May 22, 2014**

**ZIOPHARM Oncology, Inc.**  
**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**One First Avenue, Parris Building 34, Navy Yard Plaza**

**001-33038**  
**(Commission**

**File Number)**

**84-1475672**  
**(IRS Employer**

**Identification No.)**

**02129**

**Boston, Massachusetts**  
**(Address of Principal Executive Offices)**  
**(617) 259-1970**

**(Zip Code)**

**(Registrant's telephone number, including area code)**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 7.01 Regulation FD Disclosure**

On May 22, 2014, ZIOPHARM Oncology, Inc., or the Company, announced the presentation of results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. The presentation, titled Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Immunotherapy, was presented in an oral session at the 17th Annual Meeting of the American Society of Gene and Cell Therapy, held May 21-24 in Washington, D.C.

A copy of the above referenced press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the above referenced presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. This information, including the information contained in the press release furnished as Exhibit 99.1 and the presentation furnished as Exhibit 99.2, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of the Company dated May 22, 2014
99.2	Presentation of the Company dated May 22, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

Date: May 22, 2014

By: /s/ Kevin G. Lafond  
Name: Kevin G. Lafond  
Vice President, Chief Accounting Officer and  
Title: Treasurer

**INDEX OF EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release of the Company dated May 22, 2014
99.2	Presentation of the Company dated May 22, 2014